StockData
Boston Scientific Corp logo

Boston Scientific Corp (BSX) stock

BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3053% below fair value
$43.64+0.61 (+1.42%)

Close on Nov 18, 2026Market cap $63.24BP/E 17.7Yield –

Boston Scientific operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Boston Scientific's operating income for the twelve months ending Jun 30, 2026 was $4.15B, up 31.9% year over year. For fiscal 2025 it was $3.61B, up 38.8% from the year before. The highest annual figure on record is $3.61B in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.61B+38.8%
FY2024Dec 31, 2024$2.60B+11.1%
FY2023Dec 31, 2023$2.34B+42.1%
FY2022Dec 31, 2022$1.65B+37.5%
FY2021Dec 31, 2021$1.20B–
FY2020Dec 31, 2020-$80.00M-105.3%
FY2019Dec 31, 2019$1.52B+0.8%
FY2018Dec 31, 2018$1.51B+17.2%
FY2017Dec 31, 2017$1.29B+187.5%
FY2016Dec 31, 2016$447.00M–
FY2015Dec 31, 2015-$283.00M–
FY2014Dec 31, 2014-$301.00M-350.8%
FY2013Dec 31, 2013$120.00M–
FY2012Dec 31, 2012-$3.87B-527.9%
FY2011Dec 31, 2011$904.00M–
FY2010Dec 31, 2010-$656.00M–
FY2009Dec 31, 2009-$894.00M–
FY2008Dec 31, 2008-$1.51B–
FY2007Dec 31, 2007-$14.00M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.18B+43.8%
Q1 FY2026Mar 31, 2026$1.10B+19.5%
Q4 FY2025Dec 31, 2025$825.00M+22.2%
Q3 FY2025Sep 30, 2025$1.05B+43.0%
Q2 FY2025Jun 30, 2025$819.00M+57.5%
Q1 FY2025Mar 31, 2025$921.00M+36.4%
Q4 FY2024Dec 31, 2024$675.00M+15.6%
Q3 FY2024Sep 30, 2024$733.00M+5.8%
Q2 FY2024Jun 30, 2024$520.00M+1.2%
Q1 FY2024Mar 31, 2024$675.00M+22.3%
Q4 FY2023Dec 31, 2023$584.00M+45.3%
Q3 FY2023Sep 30, 2023$693.00M+93.6%
Q2 FY2023Jun 30, 2023$514.00M+21.5%
Q1 FY2023Mar 31, 2023$552.00M+18.5%
Q4 FY2022Dec 31, 2022$402.00M+123.3%
Q3 FY2022Sep 30, 2022$358.00M-7.5%
Q2 FY2022Jun 30, 2022$423.00M+61.5%
Q1 FY2022Mar 31, 2022$466.00M+25.9%
Q4 FY2021Dec 31, 2021$180.00M+260.0%
Q3 FY2021Sep 30, 2021$387.00M–
Q2 FY2021Jun 30, 2021$262.00M–
Q1 FY2021Mar 31, 2021$370.00M+153.4%
Q4 FY2020Dec 31, 2020$50.00M-76.2%
Q3 FY2020Sep 30, 2020-$205.00M-153.5%
Q2 FY2020Jun 30, 2020-$71.00M-118.5%
Q1 FY2020Mar 31, 2020$146.00M-73.0%
Q4 FY2019Dec 31, 2019$210.00M-34.2%
Q3 FY2019Sep 30, 2019$383.00M-1.3%
Q2 FY2019Jun 30, 2019$384.00M-2.0%
Q1 FY2019Mar 31, 2019$541.00M+32.9%
Q4 FY2018Dec 31, 2018$319.00M+0.3%
Q3 FY2018Sep 30, 2018$388.00M+2.9%
Q2 FY2018Jun 30, 2018$392.00M+74.2%
Q1 FY2018Mar 31, 2018$407.00M+11.8%
Q4 FY2017Dec 31, 2017$318.00M+127.1%
Q3 FY2017Sep 30, 2017$377.00M+8.3%
Q2 FY2017Jun 30, 2017$225.00M–
Q1 FY2017Mar 31, 2017$364.00M–
Q4 FY2016Dec 31, 2016$140.00M–
Q3 FY2016Sep 30, 2016$348.00M–

More Boston Scientific figures

See a number that looks wrong?